Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis.
Dominick Bossé(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Andrew W. Hahn(The University of Texas MD Anderson Cancer Center), Sumanta K. Pal(City of Hope), Sabina Signoretti(Brigham and Women's Hospital), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Rana R. McKay(University of California San Diego), Thai H. Ho(Mayo Clinic in Arizona), Wanling Xie(Dana-Farber Cancer Institute), Yasser Ged(Memorial Sloan Kettering Cancer Center), Tracy L. Rose(University of North Carolina at Chapel Hill), Paulo Gustavo Bergerot(Hospital Estadual Centra), W. Kimryn Rathmell(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Pheroze Tamboli(The University of Texas MD Anderson Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Neeraj Agarwal(University of Utah), Guillermo de Velasco(Hospital Universitario 12 De Octubre), Daniel Yick Chin Heng(University of Calgary), Leonard J. Appleman(University of Pittsburgh)
Cited by 9
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k